checkAd

     127  0 Kommentare American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia - Seite 3

    1 Potkin et al. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study. J Clin Psych, 2020;81(2):19m12769. https://doi.org/10.4088/JCP.19m12769

    2American Psychiatric Association. Schizophrenia Spectrum and Other Psychiatric Disorders. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.

    3 National Institutes of Health. Schizophrenia. Accessed on August 14, 2020 from https://archives.nih.gov/asites/report/09-09-2019/report.nih.gov/nihfactsheets/Pdfs/Schizophrenia(NIMH).pdf.

    4 Merikangas et al. Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2007 May; 64(5): 543–552.  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931566/

    Alkermes Contacts:



    For Investors:

    Sandy Coombs,

    +1 781 609 6377

    For Media:

    Marisa Borgasano,

    +1 781 609 6659

    Alkermes plc Logo

    Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg

    Lesen Sie auch

     

    Seite 3 von 3



    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia - Seite 3 DUBLIN, Aug. 17, 2020 /PRNewswire/ - Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, American Journal of …